Financial Statements
For the Years Ended December 31, 2019 and 2018
With Independent Auditor's Report



Financial Statements
Years Ended December 31, 2019 and 2018

TABLE OF CONTENTS

	<u>Page(s)</u>
INDEPENDENT AUDITOR'S REPORT	1–2
FINANCIAL STATEMENTS	
Balance Sheets	3
Statements of Operations	4
Statements of Members' Equity	5
Statements of Cash Flows	6
Notes to Financial Statements	7–24



INDEPENDENT AUDITOR'S REPORT

Board of Directors Hudson Hospital-Opco, LLC (d/b/a Christ Hospital) Jersey City, New Jersey

Report on the Financial Statements

We have audited the accompanying financial statements of Hudson Hospital-Opco, LLC (d/b/a Christ Hospital), which comprise the balance sheet as of December 31, 2019, the related statements of operations, changes in members' equity, and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

Basis for Qualified Opinion

The Hospital contracts with a related-party physicians' practice groups. The balance sheet includes a due from its physicians' practice group of \$21,458,733 at December 31, 2019 and the statement of operations includes related physician fees to the physicians' practice group of approximately \$18,188,053 for the year then ended. We were unable to obtain documentation to support the collectability of the balance due from the physicians' practice group, nor were we able to reconcile the activity recorded during the year by other auditing procedures.

Qualified Opinion

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion paragraph, the financial statements referred to above present fairly, in all material respects, the financial position of Hudson Hospital-Opco, LLC (d/b/a Christ Hospital) as of December 31, 2019, and the results of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Prior-Period Financial Statements

Mitchell: Titus, LLP

The financial statements of Hudson Hospital-Opco, LLC (d/b/a Christ Hospital) for the year ended December 31, 2018, were audited by another auditor whose report dated September 6, 2019 included an emphasis-of-matter paragraph that described the substantial doubt about its ability to continue as a going concern as discussed in Note 2 to the financial statements, and expressed an unmodified opinion on those statements.

Emphasis of Matter

The accompanying financial statements have been prepared assuming that the Hospital will continue as a going concern. As discussed in Notes 2 and 8 to the financial statements, the Hospital has suffered recurring losses from operations, has a net working capital deficiency and has significant debt that is subject to a short-term forbearance agreement questioning its ability to meet its obligations. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

July 25, 2022

Balance Sheets As of December 31, 2019 and 2018

	2019	2018
ASSETS		
Current assets		
Cash and cash equivalents	\$ 8,101,675	\$ 6,795,912
Net patient accounts receivable, current portion	33,947,008	32,983,999
Other receivables	20,870	8,294,671
Due from third-party payors	4,538,318	-
Due from related parties	78,955	345,694
Other assets	4,073,850	5,882,787
Total current assets	50,760,676	54,303,063
Net patient accounts receivable, less current portion	33,139,950	25,507,063
Intangible assets, net	8,266,800	9,463,900
Due from related parties	26,064,825	21,353,243
Investments in unconsolidated entities	3,047,611	3,047,611
Property and equipment, net	47,835,713	54,076,622
Total assets	\$169,115,575	\$167,751,502
LIABILITIES AND MEMBERS' EQUITY Current liabilities		
Accounts payable	\$ 12,020,410	\$ 12,461,786
Accrued compensation and other accrued expenses	6,482,011	11,740,775
Due to related parties	58,637,266	45,068,280
Deferred revenue	1,489,583	1,056,684
Due to third-party payors, current portion	134,059	11,371,096
Capital lease payable, current portion	5,075,799	4,828,751
Line of credit	, , , <u>-</u>	24,372,841
Loan payable	36,991,936	-
Total current liabilities	120,831,064	110,900,213
Due to third-party payors, less current portion	4,006,682	5,006,682
Capital lease payable, less current portion	39,943,838	45,019,638
Total liabilities	164,781,584	160,926,533
Members' equity	4,333,991	6,824,969
Total liabilities and members' equity	\$169,115,575	\$167,751,502

The accompanying notes are an integral part of these financial statements.

Statements of Operations
For the Years Ended December 31, 2019 and 2018

	2019	2018
REVENUE		
Net patient service revenue	\$ 180,023,800	\$ 189,465,377
Charity care subsidy	12,240,102	11,537,112
Other revenue	2,033,200	1,878,105
Total revenue	194,297,102	202,880,594
EXPENSES		
Salaries and wages	65,179,807	66,873,183
Fringe benefits	12,608,092	13,148,673
Physician fees	1,857,336	1,879,660
Supplies and other expenses	85,377,579	104,287,618
Interest expense	6,112,883	4,493,259
Depreciation and amortization	7,448,830	8,409,264
Other transfers - funding to physician practice groups	18,188,053	14,731,649
Total expenses	196,772,580	213,823,306
OTHER INCOME/(EXPENSE)		
Interest income	90,506	2,262
Net loss	\$ (2,384,972)	\$ (10,940,450)

Statements of Members' Equity For the Years Ended December 31, 2019 and 2018

Members' equity, December 31, 2017	\$	17,848,538
Net loss	((10,940,450)
Member distributions		(83,119)
Members' equity, December 31, 2018		6,824,969
Net loss		(2,384,972)
Member distributions		(106,006)
Members' equity, December 31, 2019	\$	4,333,991

The accompanying notes are an integral part of these financial statements.

Statements of Cash Flows

For the Years Ended December 31, 2019 and 2018

CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) \$ (2,384,972) \$ (10,940,450) Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities Depreciation 6,251,730 7,212,164 Amortization 1,197,100 1,197,100 Gain on settlement (90,506) - Disposal of IT software 192,244 - Change in present value of other receivables - 1,508,634 Changes in assets and liabilities (Increase) (8,595,896) (8,123,182) Other receivables 3,364,907 (4,252,234) (10,76,690) Increase (decrease in 4308,937 (977,690) (10,76,690) (1,376,456) (2,528,764) 3,054,699 (1,376,456) (2,528,764) 3,054,699 (1,376,456) (2,528,764) 3,054,699 (1,376,456) (2,284,289) 1,056,684 (1,6775,355) 12,141,764 (1,6775,355) 12,141,764 (1,6775,355) 12,141,764 (1,6775,355) 12,141,764 (1,6775,355) 12,141,764 (1,6775,355) 12,141,764 (1,6775,355) <td< th=""><th></th><th>2019</th><th>2018</th></td<>		2019	2018
Net income (loss) \$ (2,384,972) \$ (10,940,450) Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities 6,251,730 7,212,164 Depreciation 6,251,730 7,212,164 Amortization 1,197,100 1,197,100 Gain on settlement (90,506) - Disposal of IT software 192,244 - Change in present value of other receivables - 1,508,634 Changes in assets and liabilities (Increase) (8,595,896) (8,123,182) Other receivables 8,364,307 (4,252,234) Other receivables 8,364,307 (4,252,234) Other reses (decrease) in (441,376) 1,376,456 Accounts payable (441,376) 1,376,456 Accursed compensation and other accrued expenses (5,258,764) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (203,065) (4	CASH FLOWS FROM OPERATING ACTIVITIES		
Depreciation		\$ (2,384,972)	\$ (10,940,450)
Depreciation	Adjustments to reconcile net income (loss) to net cash	,	,
Amortization	(used in) provided by operating activities		
Gain on settlement (90,506) - Disposal of IT software 192,244 - Change in present value of other receivables - 1,508,634 Changes in assets and liabilities (Increase) decrease in - 1,508,634 Net patient accounts receivable (8,595,896) (8,123,182) Other receivables 8,364,307 (4,252,234) Other assets 1,808,937 (977,690) Increase (decrease) in 441,376 1,376,456 Accounts payable (441,376) 1,376,456 Accrued compensation and other accrued expenses (5,258,764) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Tube transparent of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities	Depreciation	6,251,730	7,212,164
Disposal of IT software	Amortization	1,197,100	1,197,100
Change in present value of other receivables - 1,508,634 Changes in assets and liabilities (Increase) decrease in (8,595,896) (8,123,182) Other receivables 8,364,307 (4,252,234) Other assets 1,808,937 (977,690) Increase (decrease) in (441,376) 1,376,456 Accounts payable (441,376) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Variable of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments<		` ' '	-
Changes in assets and liabilities (Increase) decrease in (8,595,896) (8,123,182) Other receivables 8,364,307 (4,252,234) Other assets 1,808,937 (977,690) Increase (decrease) in 4Accounts payable (441,376) 1,376,456 Accrued compensation and other accrued expenses (5,258,764) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Variable of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752)	·	192,244	-
Net patient accounts receivable	• .	-	1,508,634
Net patient accounts receivable (8,595,896) (8,123,182) Other receivables 8,364,307 (4,252,234) Other assets 1,808,937 (977,690) Increase (decrease) in (441,376) 1,376,456 Accrued compensation and other accrued expenses (5,258,764) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES 203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES (106,006) (83,119) Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net	_		
Other receivables 8,364,307 (4,252,234) Other assets 1,808,937 (977,690) Increase (decrease) in (441,376) 1,376,456 Accrued compensation and other accrued expenses (5,258,764) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Value of third-party and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 (Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities 7,684,337 (2,337,864) </td <td>· · · · · · · · · · · · · · · · · · ·</td> <td></td> <td></td>	· · · · · · · · · · · · · · · · · · ·		
Other assets 1,808,937 (977,690) Increase (decrease) in (441,376) 1,376,456 Accounts payable (441,376) 1,376,456 Accrued compensation and other accrued expenses (5,258,764) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES (106,006) (83,119) Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities <td>·</td> <td>,</td> <td>,</td>	·	,	,
Increase (decrease) in			` ,
Accounts payable (441,376) 1,376,456 Accrued compensation and other accrued expenses (5,258,764) 3,054,699 Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Variable of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents 1,305,763 (116,538) Cash		1,808,937	(977,690)
Accrued compensation and other accrued expenses Due to related parties, net Due to related parties, net Deferred revenue Due to third-party payors CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Investments in unconsolidated entity Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Purchase of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (106,00		(444.070)	4 070 450
Due to related parties, net 9,124,143 3,098,322 Deferred revenue 432,899 1,056,684 Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents 1,305,763 (116,538) Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year <t< td=""><td>· ·</td><td>` '</td><td></td></t<>	· ·	` '	
Deferred revenue		,	
Due to third-party payors (16,775,355) 12,141,764 Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (2,30,65) (1,822,648) Investments in unconsolidated entity (2,308,293) (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES (106,006) (83,119) Member distributions (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net (2,337,864) (36,991,936) - Net cash provided by (used in) financing activities (2,337,864) (2,337,864) Net increase (decrease) in cash and cash equivalents (2,337,864) (3,05,763) (116,538) Cash and cash equivalents, beginning of year (3,795,912) (6,912,450) Cash and cash equivalents, end of year (3,795,912) (6,795,912) SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	• • • • • • • • • • • • • • • • • • • •		
Net cash (used in) provided by operating activities (6,175,509) 6,352,267 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents 1,305,763 (116,538) Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year \$8,101,675 \$6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION		•	
CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents 1,305,763 (116,538) Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year \$8,101,675 \$6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION			
Purchase of property and equipment (203,065) (1,822,648) Investments in unconsolidated entity - (2,308,293) Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents 1,305,763 (116,538) Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year \$8,101,675 \$6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Net cash (used in) provided by operating activities	(6,175,509)	6,352,267
Investments in unconsolidated entity Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (Payments) proceeds from line of credit, net (Payments) proceeds from line of credit, net (24,372,841) (Payment of capital lease obligation, net of payments (Proceeds from loan payable, net Net cash provided by (used in) financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	CASH FLOWS FROM INVESTING ACTIVITIES		
Net cash used in investing activities (203,065) (4,130,941) CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (106,006) (83,119) (Payments) proceeds from line of credit, net (24,372,841) 2,338,981 Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net 36,991,936 - Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents 1,305,763 (116,538) Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year \$8,101,675 \$6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Purchase of property and equipment	(203,065)	(1,822,648)
CASH FLOWS FROM FINANCING ACTIVITIES Member distributions (Payments) proceeds from line of credit, net (Payments) proceeds from line of capital lease obligation, net (Payments) proceeds from line of capital lease obligation, net (Payments) proceeds from line of capital lease obligation, net (Payments) proceeds from line of capital lease obligation, net (Payments) proceeds from line of capital lease obligation, net (Paymen	Investments in unconsolidated entity	<u> </u>	(2,308,293)
Member distributions(106,006)(83,119)(Payments) proceeds from line of credit, net(24,372,841)2,338,981Repayment of capital lease obligation, net of payments(4,828,752)(4,593,726)Proceeds from loan payable, net36,991,936-Net cash provided by (used in) financing activities7,684,337(2,337,864)Net increase (decrease) in cash and cash equivalents1,305,763(116,538)Cash and cash equivalents, beginning of year6,795,9126,912,450Cash and cash equivalents, end of year\$8,101,675\$6,795,912SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Net cash used in investing activities	(203,065)	(4,130,941)
(Payments) proceeds from line of credit, net Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	CASH FLOWS FROM FINANCING ACTIVITIES		
(Payments) proceeds from line of credit, net Repayment of capital lease obligation, net of payments (4,828,752) (4,593,726) Proceeds from loan payable, net Net cash provided by (used in) financing activities 7,684,337 Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Member distributions	(106,006)	(83,119)
Proceeds from loan payable, net Net cash provided by (used in) financing activities 7,684,337 Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION 136,991,936 7,684,337 (2,337,864) 1,305,763 (116,538) 6,795,912 5,912,450 \$ 8,101,675 \$ 6,795,912	(Payments) proceeds from line of credit, net	` '	,
Net cash provided by (used in) financing activities 7,684,337 (2,337,864) Net increase (decrease) in cash and cash equivalents 1,305,763 (116,538) Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year \$8,101,675 \$6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	· ·	•	(4,593,726)
Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION 1,305,763 1,305,763 6,795,912 6,912,450 \$ 8,101,675 \$ 6,795,912	Proceeds from loan payable, net	·	-
Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year \$ 8,101,675 \$ 6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Net cash provided by (used in) financing activities	7,684,337	(2,337,864)
Cash and cash equivalents, beginning of year 6,795,912 6,912,450 Cash and cash equivalents, end of year \$ 8,101,675 \$ 6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Net increase (decrease) in cash and cash equivalents	1 305 763	(116 538)
Cash and cash equivalents, end of year \$8,101,675 \$6,795,912 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	· · · · · · · · · · · · · · · · · · ·		, ,
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION			
INFORMATION	Cash and cash equivalents, end of year	\$ 6,101,675	\$ 6,795,912
		\$ 6,255,188	\$ 4,236,601

The accompanying notes are an integral part of these financial statements.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 1 DESCRIPTION OF THE ORGANIZATION

Hudson Hospital-Opco, LLC (d/b/a Christ Hospital) (the Hospital) is a wholly owned subsidiary of CH Hudson Holdco, LLC (CH Hudson Holdco). The Hospital facilitates the operations of Christ Hospital, which was acquired out of bankruptcy through an asset purchase agreement in 2012. The Hospital is a licensed 349 bed acute care facility that provides inpatient and outpatient services.

NOTE 2 FINANCIAL AND LIQUIDITY CONSIDERATION

As both the inpatient and outpatient volumes continue to decline, the Hospital has taken various initiatives to remain financially viable and address liquidity concerns. During 2019, the Hospital refinanced its line of credit with a financial institution by entering into both a First-Out Term Loan in the amount of \$20,000,000 and a Last-Out Term Loan in the amount of \$17,951,721 (collectively, the Loans). In addition to providing the funds to make the final debt service payment on the line of credit \$(12,231,021), the term loans provided a \$25,750,700 cash infusion to the Hospital. Subsequent to December 31, 2019, the Hospital paid the entire balance of \$20,000,000 of the outstanding balance on the First-Out Term Loan and has modified the forbearance agreement for the Last-Out Term Loan, extending the maturity date to April 30, 2021. The Last-Out Term Loan is with a related party and no additional extensions have been executed. In addition, the Hospital has received payments of \$70,662,000 from the general stimulus and safety net distributions of the Provider Relief Fund (PRF) from the U.S. Department of Health and Human Services (HHS) as part of the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act). The funds received from HHS are subject to specific terms, conditions and audit by HHS. Noncompliance with any of the terms or conditions is grounds for HHS to recoup some or all of the payments received by the Hospital. For the year ending December 31, 2021, the Hospital has unaudited earnings before interest, taxes, depreciation and amortization (EBITDA) of \$7,500,000, and at the time of the issuance of these financial statements there was cash on hand of \$11.2 million.

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The financial statements of the Hospital have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

Cash and Cash Equivalents

The Hospital considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Net Patient Accounts Receivable

Net patient accounts receivable are reported at estimated net realizable value. Management's estimate of net realizable value is based on historical collection patterns and does not distinguish between contractual allowances and allowances for doubtful accounts. Individual patient accounts are written off when they are determined to be uncollectible based upon management's periodic review of the accounts receivable aging, payor classifications and application of historical write-off percentages.

Net patient accounts receivable consist primarily of balances due from third-party insurers for services to patients. Management performs periodic analyses to evaluate the net realizable value of accounts receivable. These estimates were calculated based on the Hospital's previous subsequent collections history and ongoing collection efforts. The timing of collections and the ultimate amounts collected may materially differ from such estimates. The Hospital does not impute interest on its accounts receivable.

The Hospital's experience indicates that the normal collection cycle for certain accounts extends beyond 12 months. Accordingly, the estimates of accounts expected to settle after 12 months from the balance sheet dates are classified as noncurrent assets.

Investments in Unconsolidated Entities

The Hospital records its investment in unconsolidated entities, using the cost method of accounting where its investment is less than 20%. Any earnings distributions received are included in the net income or loss during the year. The Hospital has other investments that are not accounted for in accordance with U.S. GAAP.

Property and Equipment

Property and equipment are recorded at their aggregate purchase cost, apportioned to individual assets on the basis of fair market value at the date of acquisition. Depreciation is provided over the estimated useful life for each class of depreciable assets and is computed using the straight-line method. The estimated useful lives of various asset classes are as follows:

Building and building improvements 5–15 years Fixed equipment 10 years Major moveable equipment 5–7 years

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Intangible Assets

Intangible assets arising from business combinations are recognized at fair value at the date of acquisition. Effective January 1, 2018, the Hospital adopted the provisions of Accounting Standards Update (ASU) 2014-02 Intangibles-Goodwill and Other: Accounting for Goodwill (A Consensus of the Private Company Council) and ASU 2016-03, Intangibles-Goodwill and Other (Topic 350), Business Combinations, Consolidation, Derivatives and Hedging: Effective Date and Transition Guidance (A Consensus of Private Company Council), which allow a private company to elect the accounting alternative for amortizing intangible assets. Intangible assets are being amortized using the straight-line method for a period of 10 years.

Revenue Recognition

Net operating revenues are recognized in the period services are performed and consist primarily of the net patient service revenue that is reported at estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustments under reimbursement agreements with third-party payors. Retroactive reimbursement adjustments are estimated in the period in which the related services are rendered and adjusted in future periods as final settlements are determined. Payment arrangements with third-party payors include prospectively determined rates per discharge, reimbursed costs, charges, discounted charges and per diem payments.

Income Taxes

As a limited liability company, the net income of the Hospital passes through to the tax returns of the respective owners, and income tax expense is not reported as an element of expense in the Hospital's financial statements. Furthermore, as the Hospital is a solely owned limited liability company, it is considered to be a disregarded entity under the tax code and does not file a tax return. In addition, the Hospital has not taken an uncertain tax position that would require provision of a liability in accordance with U.S. GAAP.

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Concentration of Credit Risk

The Hospital is located in the State of New Jersey. The Hospital extends credit for all customers without collateral, most of who are local residents that are insured under various third-party payor insurance programs. Credit losses are provided for in the financial statements and consistently have been within management's expectations.

The mix of receivables from primary payor sources, including patients and third parties is as follows:

	December 31,		
	2019 (%)	2018 (%)	
Medicare	6	8	
Medicaid	2	6	
Other third-party payors	92	86	

Financial instruments that potentially subject the Hospital to concentrations of credit risk consist primarily of cash and cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) insurance limits. At various times during the year, the Hospital may have cash deposits at financial institutions in excess of FDIC insurance limits. These financial institutions have strong credit ratings, and management believes that credit risk related to these accounts is minimal.

Reclassifications

Certain prior-year amounts have been reclassified to conform to the current-year presentation.

Adopted Accounting Pronouncements

Classification of Certain Cash Receipts and Cash Payments (Topic 230)

In August 2016, the Financial Accounting Standards Board (FASB) issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230), which clarifies how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments are intended to reduce diversity in practice. This ASU contains additional guidance clarifying when an entity should separate cash receipts and cash payments and classify them into more than one class of cash flows (including when reasonable judgment is required to estimate and allocate cash flows) versus when an entity should classify the aggregate amount into one class of cash flows on the basis of predominance. The adoption of ASU 2016-15 did not have an impact on the Hospital's financial statements for the year ended December 31, 2019.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Adopted Accounting Pronouncements (continued)

Statement of Cash Flows: Restricted Cash (Topic 230)

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows:* Restricted Cash (Topic 230), to address the classification and presentation of changes in restricted cash on the statement of cash flows. The ASU requires that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash and restricted cash equivalents. Thus, amounts generally described as restricted cash or restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The adoption of ASU 2016-18 did not have an impact on the Hospital's financial statements for the year ended December 31, 2019.

Recent Accounting Pronouncements Issued but Not Yet Adopted

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers (Topic 606)*, which is comprehensive new revenue recognition guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The FASB issued ASU 2020-05, which deferred the effective date for the Hospital until annual periods beginning after December 15, 2019.

Earlier adoption is permitted, subject to certain limitations. The amendments in this update are required to be applied retrospectively to each prior reporting period presented or with the cumulative effect being recognized at the date of initial application. The Hospital does not believe the pending adoption of ASU 2014-09 will have a material impact on the Hospital's financial statements.

Leases

In February 2016, the FASB issued ASU 2016-02, *Leases (Topic 842)*, which will require lessees to recognize a lease liability, which is a lessee's obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee's right to use, or control the use of, a specified asset for the lease term. The FASB issued ASU 2020-05, which deferred the effective date for the Hospital until annual periods beginning after December 15, 2021. Management is currently evaluating the impact of ASU 2016-02 on the Hospital's financial statements.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Recent Accounting Pronouncements Issued but Not Yet Adopted (continued)

Intangible Assets

In January 2017, the FASB issued ASU 2017-04, *Intangibles-Goodwill and Other (Topic 350)*, to simplify how all entities assess goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As amended, the goodwill impairment test will consist of one step comparing the fair value of a reporting unit with its carrying amount. An entity should recognize a goodwill impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The standard is effective for non-public business entities for fiscal years beginning after December 15, 2021. The Hospital does not believe the pending adoption of ASU 2017-04 will have a material impact on the financial statements.

NOTE 4 NET PATIENT SERVICE REVENUE

The Hospital has agreements with Medicare, Medicaid and other third-party payors that provide for payments to the Hospital at amounts different from its established rates. A summary of the payment arrangements with third-party payors follows:

Medicare

Under the Medicare program, the Hospital receives reimbursement under a prospective payment system for inpatient and outpatient services. The Hospital's reimbursements from Medicare are subject to certain variations under Medicare's single bundled payment rate system, whereby reimbursements can be adjusted for certain patient characteristics and other factors. Federal regulations provide for certain adjustments to current and prior years' payment rates, based on industry wide and hospital specific data. The Hospital has been audited and received final settlements on its Medicare cost reports through 2017 and tentative settlements through 2020.

Non-Medicare Payments

Services rendered to Medicaid program beneficiaries are paid at prospectively determined rates that vary based on clinical, diagnostic and other factors. Revenues associated with commercial health plans and health maintenance organizations are based on contractual terms. Non-contracted health plan revenue is based on historical collection experience.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 4 NET PATIENT SERVICE REVENUE (continued)

Regulation and Reimbursement Contingencies

Regulations require annual retroactive settlements for cost-based reimbursements through cost reports filed by the Hospital. These retroactive settlements are estimated and recorded in the financial statements in the year in which they become known. The estimated settlements recorded at December 31, 2019 and 2018 could differ from actual settlements based on the results of the cost report audits.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. The Hospital is not aware of any allegations of noncompliance that could have a material adverse effect on the accompanying financial statements and believes it is in compliance, in all material respects, with the applicable laws and regulations. Action for noncompliance could result in repayment of amounts improperly reimbursed, fines, penalties and exclusion from Medicare and Medicaid programs.

NOTE 5 INTANGIBLE ASSETS, NET

The composition of the intangible assets, net is summarized as follows:

	December 31, 2019					
		Gross Balance		ccumulated mortization	 Net Value	Useful Life
Licenses Trade name Medical records	\$	5,000,000 2,400,000 4,571,000	\$	1,000,000 1,790,000 914,200	\$ 4,000,000 610,000 3,656,800	10 years 10 years 10 years
Total	\$	11,971,000	\$	3,704,200	\$ 8,266,800	
December 31, 2018						
		Gross Balance		ccumulated mortization	Net Value	Useful Life
Licenses Trade name Medical records	\$	5,000,000 2,400,000 4,571,000	\$	500,000 1,550,000 457,100	\$ 4,500,000 850,000 4,113,900	10 years 10 years 10 years
Total	\$	11,971,000	\$	2,507,100	\$ 9,463,900	

During the years ended December 31, 2019 and 2018, amortization expense was \$1,197,100 for both years. Finite lived intangible assets are amortized under the straight-line method.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 6 PROPERTY AND EQUIPMENT, NET

Property and equipment, net, consists of the following as of December 31:

	2019	2018
Land and building	\$ 78,053,827	\$ 78,053,827
Building improvements	1,596,394	1,283,458
Movable and fixed equipment	29,549,834	29,178,478
Construction-in-progress	1,266,393	1,939,865
Less: Accumulated depreciation	110,466,448 62,630,735	110,455,628 56,379,006
	\$ 47,835,713	\$ 54,076,622

During 2019 and 2018, the Hospital had property and equipment additions of \$203,065 and \$1,822,648, respectively.

Costs incurred to date on projects included in construction-in-progress as of December 31, 2019 and 2018 and represent approximately 45% and 40%, respectively, of the project construction costs.

The Hospital is obligated under capital leases covering building and equipment that expire at various dates through 2027. The gross amount of building and equipment and related accumulated depreciation recorded under the capital lease were as follows as of December 31:

	 2019	 2018
Land and building	\$ 75,611,105	\$ 75,611,105
Equipment	6,533,503	6,533,503
Less: Accumulated depreciation	 41,813,470	 36,772,730
	\$ 40,331,138	\$ 45,371,878

NOTE 7 LINE OF CREDIT

At December 31, 2018, the Hospital had the ability to borrow from a financial institution up to \$25,000,000, which was secured by the Hospital's patient accounts receivable. Interest on outstanding advances under the line was due and payable on a monthly basis at an annual interest rate of the London Interbank Offered Rate plus 3.50%. At December 31, 2018, the outstanding amount on the line was \$24,372,841. The Hospital was required to comply with certain covenants under its line of credit agreement. At December 31, 2018, covenants were not complied with nor waived by the financial institution. Therefore, the Hospital line of credit was in default and was classified as current liabilities. This line of credit was subsequently replaced by term loans (see Note 8).

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 8 LOANS PAYABLE

On June 26, 2019, the Hospital entered into a First-Out Term Loan and Last-Out Term Loan (collectively, the credit agreement) in an aggregate amount of \$37,951,721, consisting of a) a senior secured multi-draw term loan facility in an aggregate principal amount of \$20,000,000 funded by a lender (First-Out Term Loan) and b) a senior secured multi-draw term loan facility in an aggregate principal amount of \$17,951,721 funded by a private group (Last-Out Term Loan). In conjunction with entering the credit agreement, the Hospital paid in full its previous line of credit with a financial institution and terminated all commitments and discharged all related guarantees. The Hospital deemed the refinancing to be an extinguishment of the old debt in accordance with FASB Accounting Standards Codification 470, Debt, which resulted in a write-off of the prior issuance costs and recognition of new issuance costs. Both the First-Out Term Loan and the Last-Out Term Loan require no amortization and have a stated maturity date of 12 months. During the term of the credit agreement, interest on the First-Out Term Loan accrues at 12.00% and is payable in cash monthly in arrears. Interest accrues on the Last-Out Term Loan at 12.50% and is capitalized and thereafter treated as principal. At December 31, 2019, the outstanding amount of the term loans was \$36,991,936. At December 31, 2019, various covenants were not complied with nor waived by the financial institution. Therefore, the Hospital loans payable was in default and was classified as current liabilities.

In addition to a structuring fee of 1.00% of the aggregate principal amounts of the commitments at the closing payable to the lender of the First-Out Term Loan, the Hospital will incur an exit fee of an equal amount when the loan is terminated.

Effective March 20, 2020, the Hospital entered into a forbearance agreement that, among other things, allowed for existing defaults to be offset by agreed to payments of principal, required the retention of a financial advisor as well as default interest at a rate of 14%. The forbearance agreement was amended and extended to March 31, 2021. As of March 31, 2021, the Hospital paid the entire \$20,000,000 loaned under the First-Out Term Loan.

Also, on March 31, 2021 the Hospital entered into an amendment to the forbearance agreement with the Last-Out Term Loan lender extending the agreement to April 30, 2021. A second amendment was executed extending the forbearance agreement to July 31, 2021. The Last-Out Term Loan lender is a related party and no additional extensions have been executed.

NOTE 9 CHARITY CARE

The Hospital provides services without charge, or at amounts less than its established rates, to patients who meet the criteria of its charity care policy. Because the Hospital does not pursue collection of amounts determined to qualify as charity care, such services are not reported as revenue.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 9 CHARITY CARE (continued)

The estimated cost of charity care provided was \$12,571,685 and \$16,040,374 for the years ended December 31, 2019 and 2018, respectively. The estimated cost of charity care is based on the ratio of cost-to-charges, as determined by hospital-specific data.

NOTE 10 MALPRACTICE CONTINGENCIES

Effective June 15, 2014, the Hospital purchased a claims-made policy from CarePoint Health Captive Assurance Company, LLC (the Captive), a related captive insurance provider. The policy includes no deductible for the Hospital and a \$250,000 per claim and \$750,000 in the aggregate deductible covered by the Captive, which is shared with related healthcare providers IJKG-Opco, LLC and HUMC-Opco, LLC, such that losses from all three entities would erode the \$750,000 aggregate deductible. The Hospital has also purchased excess coverage of up to \$15,000,000 from the Captive, with limits being shared among all three entities. The Captive reinsures 100% for the limits of the excess liability coverage.

Estimated malpractice liabilities are based upon actuarial valuation of the estimated effect of probable loss contingencies and determined policy deductibles. In the opinion of management, the final disposition of such claims will be within the available insurance coverage and will not have a material adverse effect on the Hospital's financial position, results of operations or liquidity.

NOTE 11 RETIREMENT PLAN

The Hospital sponsors a voluntary 401(k) profit-sharing plan (the Plan). All employees of the Hospital are eligible to participate in the Plan. Employees can contribute any amount of their compensation each pay period subject to annual limits imposed by the Internal Revenue Service and additional limits imposed by law. The employees' accounts are fully and immediately vested from their date of participation in the Plan. The Hospital also makes employer matching contributions to all eligible employees who have completed one year of service. However, the employer matching contribution is discretionary and based on the financial performance of the Hospital for the year. During the years ended December 31, 2019 and 2018, the maximum allocation that a participant can receive is 3% of the participant's compensation. Total employer contributions for the years ended December 31, 2019 and 2018 were \$935,700 and \$894,000, respectively.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 12 RELATED-PARTY TRANSACTIONS

Due from (to) Related Parties

Amounts due from (to) related parties, net, are as follows at December 31:

	2019	2018
Jersey Health Alliance, LLC Palisade Avenue Properties, LLC CarePoint Health Management Associates,	\$ 21,458,733 24,004	\$ 21,484,836 24,004
LLC	4,376,123	-
Other related parties	284,920	190,097
	26,143,780	21,698,937
Quality Care Associates, LLC	(4,847,475)	(3,236,484)
Bayonne Medical Center	(22,837,228)	(23,258,955)
Hoboken University Medical Center	(14,848,140)	(9,058,709)
Hudson Hospital HOLDCO, LLC	(6,242,633)	(6,242,633)
Sequoia Healthcare Management, LLC CarePoint Health Management Associates,	(4,869,214)	(2,297,567)
LLC	-	(557,265)
Hudson Hospital PROPCO, LLC	(4,992,576)	(416,667)
	(58,637,266)	(45,068,280)
	\$ (32,493,486)	\$ (23,369,343)

Capital Lease

The Hospital signed a 15-year lease agreement with Hudson Hospital Propco, LLC (Propco) for use of the building attained through the asset purchase on July 13, 2012. Lease payments made by the Hospital to Propco totaled \$3,230,853 and \$7,678,120 for the years ended December 31, 2019 and 2018, respectively. Propco and the Hospital are wholly owned subsidiaries of CH Hudson Holdco. During 2019, the Hospital had been precluded from making intercompany cash transfers by the lender; however, it is allowed to pay amounts suitable for Propco to make the related monthly mortgage payment. The lease also provides for annual increases of the Consumer Price Index, which the Hospital estimates to be 2%. The lease, which is secured by the building, requires monthly payments of principal and interest, with a rate at 5% per year.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 12 RELATED-PARTY TRANSACTIONS (continued)

Capital Lease (continued)

The following is a schedule of future minimum lease payments, including interest under the term of the leases, together with the present value of the net minimum lease payments, as of December 31, 2019.

Years Ending	Amount
2020	\$ 7,962,562
2021	8,121,813
2022	8,284,250
2023	8,449.935
2024	8,618,933
Thereafter	21,547,333
Total minimum lease payments	62,984,826
Less: Amount representing interest	(17,965,189)
Present value of net minimum lease payments	45,019,637
Less: Current portion	(5,075,799)
	\$ 39,943,838

Management Agreement

The Hospital has entered into a management service agreement with Sequoia Healthcare Management, LLC, which has common majority ownership as the parent company of the Hospital. The manager is responsible for the operations and economics of the Hospital in compliance with all applicable laws, statutes, ordinances and regulations. In return for these services, the Hospital pays a management fee of 4% of net patient service revenue. As of July 2019, the Hospital ceased the management fee. For the years ended December 31, 2019 and 2018, management fees payable were \$4,869,214 and \$2,297,567, respectively. Management fee expenses for the years ended December 31, 2019 and 2018 were \$3,597,522 and \$7,494,802, respectively.

Guaranty of Debt Service Payments

The Hospital has entered into Guaranty and Security agreements, whereby the Hospital, identified as the Guarantor, irrevocably and unconditionally guarantees the full, prompt and unconditional payment, when due, whether by acceleration or otherwise, of any and all obligations of Propco under the respective financing agreements. As of December 31, 2019, the amount owed on this loan was \$22,968,552.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 12 RELATED-PARTY TRANSACTIONS (continued)

Investment in McCabe Ambulance Services, Inc.

On November 1, 2013, the Hospital entered into a stock purchase agreement to attain ownership in McCabe Ambulance Services, Inc. (McCabe). McCabe is a comprehensive provider of emergency medical services, including both emergency and non-emergency ambulance transportation services. The Hospital invested \$1,441,731, which equated to ownership of approximately 23% of McCabe's outstanding stock. The investment is included in investments in unconsolidated entities in the accompanying balance sheets. While U.S. GAAP requires the equity-method of accounting be used, management views the investment in McCabe as strategic and the services provided critical to Hospital operations. Some of the operating losses of McCabe have not been recorded against the investment in an effort to show the intrinsic value of McCabe.

Investment in Fresenius

On June 11, 2018, the Hospital entered into a contribution agreement with a medical provider to obtain a 10% interest in a joint venture for the provision of outpatient dialysis services. The investment in the amount of \$2,308,298 is accounted for using the cost-method of accounting and is included in investments in unconsolidated entities in the accompanying balance sheets.

Practice Management

The Hospital provided advances to Jersey Health Alliance, LLC (JHA), predecessor to Quality Care Associates, LLC (collectively, Practice Management), related to the Hospital through ownership. These advances include the provision for working capital needs of the physician groups managed by Practice Management. These groups include Garden State Healthcare Associates LLC, which employs all of the traditional hospital-based physician specialties working full-time at the Hospital, and New Jersey Medical and Health Associates, LLC (d/b/a CarePoint Health Medical Group), which employs physicians acquired to provide continuity of care to the Hospital's patients. The Hospital believes that the services provided by Practice Management have been beneficial to both the Hospital and its patients. Practice Management is a management service organization formed to provide both healthcare and technology expertise to affiliated physician groups, as discussed below under Quality Care Associates, LLC (Quality). There is no contract in place with Practice Management covering this funding process.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 12 RELATED-PARTY TRANSACTIONS (continued)

Practice Management (continued)

The Hospital and Practice Management have entered into agreements defining the method of repayment of advances made to JHA by the Hospital. These agreements include interest at an annual rate of 4.94%. To secure the payment and performance in full mandated by the agreements, they are collateralized by a continuing security interest in and lien upon all of its right, title and interest in the patient accounts receivable of Practice Management. The following is a schedule of maturities of the loans receivable:

Years Ending	 Amount		
2020	\$ 78,955		
2021	325,733		
2022	342,193		
2023	359,486		
2024	 20,352,366		
Total	\$ 21,458,733		

CarePoint Health Management Associates

CarePoint Health Management Associates (CarePoint) is related through ownership and provides administrative and accounting services, including revenue cycle, financial reporting, payroll, accounts payable, etc. to the Hospital. The Hospital pays a professional services fee based on operating expenses and approximates 34% of CarePoint's annual expenses. The amount charged to the Hospital for these services was \$20,144,076 and \$32,297,835 for the years ended December 31, 2019 and 2018, respectively. At December 31, 2019 and 2018, \$4,376,123 and \$(557,265), respectively, was due from/(to) CarePoint.

Quality Care Associates, LLC

Quality is related through ownership and provides revenue cycle, office staff and other administrative functions to CarePoint Health Medical Group, Garden State Healthcare Associates, LLC among others (collectively Physician Practice Groups). The Hospital has committed to varying levels of subsidy to Quality to cover the monthly expenses of the Physician Practice Groups, when their expenses exceed cash collections. The Physician Practice Groups are not related to the Hospital through ownership and have a verbal agreement with the Hospital to exclusively provide physician services that support patient care at the Hospital. The Hospital transferred funds totaling \$18,188,053 and \$14,731,649 to Quality during the years ended December 31, 2019 and 2018, respectively, which are included in the statements of operations as other transfers – funding to Physician Practice Groups. The debt holders do not consider these payments to be a violation of any of the debt covenants.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 12 RELATED-PARTY TRANSACTIONS (continued)

IJKG OpCo, LLC (dba Bayonne Medical Center)

Bayonne Medical Center, a hospital related by ownership, provided capital to the Hospital over several years, which enabled the Hospital to pay bills as they came due. During 2019, Bayonne provided capital in the amount of \$2,057,714. There were no further cash transfers after March 2019.

HUMC Opco, LLC (dba Hoboken University Medical Center)

Hoboken University Medical Center, a hospital related by ownership, provided capital to the Hospital over several years, which enabled the Hospital to pay bills as they came due. During 2019, HUMC provided capital in the amount of \$6,816,122. There were no further cash transfers after May 2019.

Hudson Hospital Holdco, LLC

Hudson Hospital Holdco, LLC (Holdco) is the parent company of the Hospital. Holdco provided capital to the Hospital as part of the initial acquisition of the Hospital.

NOTE 13 OPERATING LEASES

The Hospital has entered into various operating lease agreements for equipment, expiring in varying years through 2023. Rental expense for the years ended December 31, 2019 and 2018 was \$6,932,068 and \$8,382,899, respectively. Future minimum payments on noncancelable leases are:

Years Ending	Amount
2020	\$ 4,256,441
2021	3,315,362
2022	2,606,712
2023	2,076,498
2024	1,209,550
Total	\$ 13,464,563

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 14 COMMITMENTS AND CONTINGENCIES

The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations is subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. Government activity continues to increase with respect to investigations and allegations concerning possible violations by healthcare providers of fraud and abuse statutes and regulations, which would result in the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Even if the Hospital were to ultimately prevail, a significant governmental inquiry or action under one of the above laws, regulations or rules could have a material adverse impact on it. The Hospital is involved in various other claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Hospital's financial position, results of operations, or liquidity.

The Hospital is a party in a lawsuit with related parties and, at this time, management and counsel have not determined if an unfavorable outcome will have a material or adverse impact on the financial statements of the Hospital.

NOTE 15 SUBSEQUENT EVENTS

The Hospital has performed subsequent events procedures through July 25, 2022, which is the date the financial statements were available to be issued. There were no other subsequent events requiring adjustment to the financial statements or disclosures, except for the following:

On March 11, 2020, the World Health Organization declared the novel coronavirus (COVID-19) a global pandemic. The COVID-19 pandemic substantially impacted the global economy, including significant volatility in financial markets. As a result of the COVID-19 pandemic, patient volumes and associated patient net revenues at the Hospital were significantly reduced in the months of March through June 2020. The Hospital began experiencing gradual and continued improvement in patient volumes in late June as stay-at-home restrictions were eased and hospitals were permitted to resume elective surgeries and procedures.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. It is uncertain what effect the pandemic will have on the Hospital's financial condition, liquidity and future results of operations. Management is actively monitoring the impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 15 SUBSEQUENT EVENTS (continued)

On March 27, 2020, the President signed into law CARES Act. The CARES Act. among other things, authorized \$100 billion in funding to hospitals and other healthcare providers to be distributed through the Provider Relief Fund (PRF). These funds are not required to be repaid, provided the recipients attest to, and comply with, certain terms and conditions, including among other things, that the funds are being used for lost operating revenues and COVID-19-related expenses. The U.S. Department of Health and Human Services (HHS) initially distributed \$30 billion of this funding based on each provider's share of total Medicare fee-for-service reimbursement in 2019. Subsequently, HHS distributed an additional \$20 billion in CARES Act funding based on an allocation proportional to the providers' share of 2018 net patient revenue. Distributions of the additional \$50 billion were targeted primarily to hospitals in COVID-19 highimpact areas, to rural providers, safety net hospitals, skilled nursing facilities and to reimburse providers for COVID-19-related treatment of uninsured patients. During the calendar year 2020, the Hospital received payments of \$70,662,000 from the general stimulus and safety net distributions of the PRF. The funds received from HHS are subject to specific terms, conditions and audit by HHS. Noncompliance with any of the terms or conditions is grounds for HHS to recoup some or all of the payments received by the Hospital. Management has attested that the funds are being used appropriately and believes it has complied with all other terms and conditions.

The CARES Act also made other forms of financial assistance available to healthcare providers, including through Medicare and Medicaid payment adjustments and an expansion of the Medicare Accelerated and Advanced Payment Program, which makes available accelerated payments of Medicare funds in order to increase cash flow to providers. In April 2020, the Hospital received \$14,760,000 of accelerated payments, which will be recorded as a liability given that recoupment will occur at some point in the future. Recoupment of these funds by Medicare began in April 2021 and is still ongoing as of July 25, 2022 with \$5,300,000 to go.

On September 19, 2020, HHS issued a Post-Payment Notice of Reporting Requirements for the PRF payments that were disbursed under the CARES Act. This notice changed guidance that had previously been communicated in June and July 2020. Key differences include introduction of the concept of calendar year measurement as opposed to quarterly measurement, the requirement to first apply stimulus monies received to healthcare related expenses attributable to COVID-19 (net of reimbursements from other sources), and change (negative change comparing 2020 over 2019) from lost revenues as defined as net patient care operating income, net of healthcare related expenses previously applied.

Notes to Financial Statements Years Ended December 31, 2019 and 2018

NOTE 15 SUBSEQUENT EVENTS (continued)

On January 15, 2021, HHS issued a Reporting Requirements Policy Update reverting back to the initial definition of lost revenues. These changing requirements may result in a change in the amount of CARES Act stimulus funds that the Hospital will be able to retain based on the terms and conditions. The Hospital had until June 30, 2021 to use the PRF toward expenses attributable to COVID-19 and complied with this requirement. The Hospital has reported their use of the PRF payments by submitting healthcare related expenses attributable to coronavirus that another source has not reimbursed and believes is not obligated to repay PRF amounts. The Hospital chose to apply PRF payments towards lost revenue based on the difference between 2019 and 2020 actual patient care revenue.

On May 9, 2022, the majority member of CH Hudson HoldCo donated it's equity in CH Hudson Holdco to CarePoint Health System, Inc. (System), a non-profit organization incorporated on November 12, 2021 for the purpose of holding the CarePoint Hospitals. System is qualified under Internal Revenue Service code section 501(c)3. Certain of the minority owners of CH Hudson HoldCo are in various stages of completing their donation to the non-profit, while other minority owners could retain their equity in CH Hudson HoldCo separate from CarePoint Health Systems, Inc.

